TSHA
$4.57
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
Recent News
Did Rett Trial Milestones Just Shift Taysha Gene Therapies' (TSHA) Gene Therapy Approval Path Narrative?
Taysha Gene Therapies recently advanced its TSHA-102 Rett syndrome program, dosing the first patient in the REVEAL pivotal phase and receiving FDA authorization to use ASPIRE trial data in a planned Biologics License Application. This combination of clinical and regulatory milestones could be important for how the company progresses its gene therapy candidate toward potential approval. Next, we’ll explore how progress in the TSHA-102 Rett syndrome program may influence Taysha Gene Therapies’...
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Taysha Gene Therapies, Inc. is placed sixth on our list of best biotech stocks under $20. TheFly reported on January 5 that Wells Fargo raised its price target on TSHA to $11 from $8 and maintained an Overweight rating. […]
Here’s What Analysts Are Saying About Taysha Gene Therapies (TSHA)
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best strong buy stocks to invest in under $5. Needham maintained a bullish outlook on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) on January 6, reiterating a Buy rating on the stock with a $10 price target. The rating update came the same day Taysha Gene Therapies, Inc. […]
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best penny stocks to buy for 2026. On January 6, the company confirmed that the dosing of the first patient in the REVELA pivotal trial began. The trial is evaluating TSHA-102, a gene therapy for Rett syndrome. The trial is poised to evaluate 15 females between […]
Does Taysha Gene Therapies Still Offer Value After a 196.8% Year to Date Surge?
Investors may be wondering if Taysha Gene Therapies at around $5.49 is still a smart bet after its big rebound, or if the easy money has already been made. The stock is down 4.7% over the last week, but it is still up 31.0% over the past month and an eye catching 196.8% year to date, with a 200.0% gain over the last year despite being 80.4% lower over five years. That kind of swingy track record usually reflects shifting sentiment around pipeline progress, regulatory milestones, partnership...